Through the fog: Recent clinical trials to preserve β-cell function in type 1 diabetes

Diabetes

Volumn 61, Issue 6, 2012, Pages 1323-1329

  Greenbaum, Carla J ^a   Schatz, Desmond A ^b   Haller, Michael J ^b   Sanda, Srinath ^a,c  

^a BENAROYA RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALUMINUM POTASSIUM SULFATE; CD3 ANTIBODY; DACLIZUMAB; GLUTAMATE DECARBOXYLASE 65; INSULIN; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXELIZUMAB; PLACEBO; PLASMID VECTOR; PROINSULIN; RAPAMYCIN; RITUXIMAB; TEPLIZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PILOT STUDY; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS;

EID: 84861868291     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1452     Document Type: Review

References (48)

1. Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 2010;33:826-832
2. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327
3. Ludvigsson J. Treatment of Type 1 Diabetes - Update on clinical Trials. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, at the San Diego Convention Center, San Diego, California
4. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
5. Schlosser M, Banga JP, Madec AM, et al. Dynamic changes of GAD65 autoantibody epitope specificities in individuals at risk of developing type 1 diabetes. Diabetologia 2005;48:922-930 (Pubitemid 40767986)
6. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007;7:988-994 (Pubitemid 350166057)
7. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005;28:1068-1076 (Pubitemid 40616615)
8. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-1755
9. Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes (INIT II). Available from http://clinicaltrials.gov/ct2/show/ NCT00336674. Accessed 6 October 2011
10. Fourlanos S, Perry C, Gellert SA, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011;60:1237-1245
11. Greenbaum CJ. Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials. Clin Immunol 2002;104:97-104 (Pubitemid 35026219)
12. Long SA, Sanda S, Buckner JH, Bollyky JB, Goland R, Bianchine P, Phippard D, Ehlers M, Greenbaum C. Rapamycin/IL-2 combination therapy in type 1 diabetics augments Treg yet transiently impairs beta cell function. Diabetes. In press
13. Gottlieb P, Eisenbarth G, Kipnes M, et al. Interim Results of a Phase I/II Clinical Trial of a DNA Plasmid Vaccine (BHT-3021) for Type 1 Diabetes. Abstract presented at the 44th Annual Meeting of the European Association for the Study of Diabetes, 7-11 September 2008, Nuova Fiera di Roma, Rome, Italy
14. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301:1573-1579
15. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-1576 (Pubitemid 46588370)
16. Annaloro C, Onida F, Lambertenghi Deliliers G. Autologous hematopoietic stem cell transplantation in autoimmune diseases. Expert Rev Hematol 2009;2:699-715
17. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-2608 (Pubitemid 41007846)
18. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91:123-127 (Pubitemid 24018655)
19. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007;7:622-632 (Pubitemid 47123550)
20. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J Clin Invest 2003;111:409-418 (Pubitemid 36182218)
21. Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature 2011;475:514-518
22. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53:614-623
23. Pozzilli P, Gottlieb P. Treatment of Type 1 Diabetes - Update on Clinical Trials. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, 24-28 June 2011, at the San Diego Convention Center, San Diego, California
24. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698 (Pubitemid 34547482)
25. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-1769 (Pubitemid 40770766)
26. Sherry N, Hagopian W, Ludvigsson J, et al.; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378:487-497
27. Gitelman S. Treatment of Type 1 Diabetes - Update on Clinical Trials. Abstract presented at the 71st Scientific Sessions of the American Diabetes Association, San Diego, California, 24-28 June 2011.
28. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-715 (Pubitemid 39173511)
29. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
30. Orban T, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet Abatacept Study Group. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011;378:412-419
31. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-860
32. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009;32:1244-1249
33. Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes (anti-IL-1). Available from http://clinicaltrials.gov/ct2/show/NCT00947427. Accessed 15 March 2011.
34. A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I. Available from http://clinicaltrials.gov/ct2/show/NCT01183468. Accessed 27 July 2011
35. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004;328:750-754 (Pubitemid 38406430)
36. Eisenbarth GS. Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes 2010;59:759-774
37. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008;205:2975-2984
38. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2008;31:2188-2192
39. Ziegler AG, Hillebrand B, Rabl W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993;36:402-408 (Pubitemid 23124043)
40. Ilonen J, Reijonen H, Herva E, et al. Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population. The Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1996;19:795-800 (Pubitemid 26286981)
41. Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996;39:807-812 (Pubitemid 26228110)
42. Knip M, Kukko M, Kulmala P, et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. Am J Med Genet 2002;115:48-54 (Pubitemid 34650722)
43. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007;8:286-298
44. Barker JM, Barriga KJ, Yu L, et al.; Diabetes Autoimmunity Study in the Young. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004;89:3896-3902 (Pubitemid 39071491)
45. Bonifacio E, Ziegler AG. Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am 2010;39:513-525
46. Mahon JL, Sosenko JM, Rafkin-Mervis L, et al.; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes 2009;10:97-104
47. Kimmelman J, London AJ. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011;8:e1001010
48. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26:832-836 (Pubitemid 36929351)